ABSORB III Trial - Baptist Health South Florida
Transcription
ABSORB III Trial - Baptist Health South Florida
Winter 2014 ABSORB III Trial: A Long-Term Test of Vascular Scaffold System N ow you see it, later you won’t. Physicians at the Institute plan to compare a new drugeluting vascular scaffold that completely resorbs over time versus current stent technology for long-term maintenance of vessel patency. Positive five year results from this ABSORB III Randomized Controlled With the ABSORB III, the scaffolding is expected to resorb after healing — within two years. Trial could signal a new era in coronary interventions, investigators say. Currently, the Institute is the only site in South Florida participating in this trial. Unlike a more permanent stent, researchers expect the scaffolding to resorb after healing — within two years. They predict this will eliminate the need for long-term dual antiplatelet therapy as the vessel remodels to a normal physiologic state. Vasoactive substances from the endothelium might even promote lumen growth, something not possible with a stent. In terms of safety, researchers are hoping for a decreased incidence of thrombosis compared to the stent, thus supporting promising results reported in earlier ABSORB trials. Patients with coronary artery disease (with vessel diameters up to 3.5 mm and up to 2 lesions) will be randomized to the ABSORBTM Bioresorbable Vascular Scaffold System (BVS) or the Xience Xpedition Everolimus Eluting Coronary Stent System and followed over five years in this Phase IV study. The ABSORB scaffold system is the first to undergo clinical trial evaluation in the United States and Institute physicians are playing an integral role in orchestrating these pivotal trials. Unlike the metal alloy stent covered in biocompatible material, the scaffold is bioresorbable poly-L-lactide, a material already used by plastic surgeons, aesthetic dermatologists and other physicians for volume replacement. Another difference is in the deployment — the scaffold material can break more easily than a metal stent so placement requires a little more finesse. For more information, please contact Ramon Quesada, M.D., Rajesh Dhairyawan, M.D., Alvaro A. Gomez, M.D., Bernardo Lopez-Sanabria, M.D., Ramon L. Lloret, M.D., Jonathan S. Roberts, M.D. or Marcus St. John, M.D. at 786-596-5992. n On the Forefront of Innovation A first-of-its-kind intervention holds significant promise for critical limb ischemia patients who require endoscopic vein harvesting. Baptist Cardiac & Vascular Institute vascular surgeon Athanassios I. Tsoukas, M.D., utilizes a technique allowing less invasive harvesting in a very sick patient under conscious sedation instead of riskier general anesthesia. The solution ended up being a solution — a tumescent combination of the vasodilator papaverine and local anesthetics xylocaine and marcaine. Dr. Tsoukas and his team slowly injected the solution around the vein under ultrasound guidance and successfully performed a femoral-popliteal bypass in this challenging patient. The patient fared well, despite a presentation that included heart disease, a cardiac ejection fraction of 20% and history of lymphoma. The technique also holds promise for other critical limb ischemia patients, especially when radiologists see anatomy unfavorable for a minimally invasive endovascular treatment. Less morbidity, quicker recovery time and less scarring compared to traditional vein bypass procedures are potential advantages. The shorter length of hospital stay afforded by the tumescent solution/minimally invasive technique could yield significant cost savings, as well. n If you prefer to receive this in an electronic format, please email [email protected]. CLINICAL TRIALS The Institute is currently involved in nearly 30 clinical trials. For more information on a specific study, please contact the Institute’s Research and Outcomes Department at 786-596-2959. New Trials and Devices Target More Patients With Resistive Hypertension As widely reported, the Symplicity HTN 3 trial failed to meet its primary efficacy endpoint and is being discontinued in the United States. Baptist Cardiac & Vascular Institute remains committed to expanding the types of technology and clinical trials designed to help patients with resistive hypertension. The Symplicity HTN 3 trial did achieve its safety endpoint. In addition, approximately eight to 10 other clinical trials evaluating the Symplicity device yielded positive results. As many as 10 devices to treat resistive hypertension are being utilized successfully in Europe. Resistive hypertension remains a formidable clinical challenge. By definition, resistive hypertension patients are on three antihypertensive medications at optimal dose, yet remain uncontrolled, with a systolic blood pressure of 160 mmHg or greater. The Institute remains at the forefront by working on the next generation of technology to treat resistive hypertension. In the near future, the Institute plans to enroll patients using a second- generation device. This device is already in use in Europe and shows promise in effectively treating resistive hypertension. Members of the Institute play essential roles in these clinical trials, including remaining active in their design and development through participation on key steering committees. For additional information, please contact Barry T. Katzen, M.D., Alex Powell, M.D., James F. Benenati, M.D., Shaun Samuels, M.D., Constantino S. Peña, M.D., Ripal T. Gandhi, M.D., Antony A. Farias, M.D. or Ian Del Conde M.D. at 786-596-5992. n Structural Heart Disease Device Studies Become More Selective I nnovative clinical trials underway at Baptist Cardiac & Vascular Institute show the promise of new medical device technologies for select patients with mitral valve insufficiency or atrial fibrillation. Careful patient selection might optimize outcomes for these structural heart disease patients considered high-risk or not suitable for traditional surgery. This is one reason researchers at the Institute are participating in the Clinical Outcomes Assessment of the MitraClip Percutaneous Therapy (COAPT). The COAPT randomized trial compares MitraClip to medical therapy in patients with functional mitral regurgitation. Driven to improve the outcomes of the Endovascular Valve Edge-to-Edge Repair Study (EVEREST) that evaluated the MitraClip Mitral Valve Repair System (Abbott Vascular, Inc.), following the EVEREST trial, researchers found high-risk surgical patients had a better outcome with MitraClip than with surgery, including lower expected mortality. Also, the investigators plan to assess efficacy of the MitraClip in patients with dilated left ventricles and severe 3+ or 4+ mitral valve insufficiencies in REALISM. REALISM is a registry of patients with severe mitral regurgitation considered high-risk for surgery. FDA approval of the MitraClip system on October 25, 2013, means many more patients can potentially benefit from this innovative treatment. Dr. Quesada, the first physician to perform the MitraClip procedure in Florida, continues his drive to optimize outcomes through ongoing enrollment in both trials. Alternatives for AFib This device received FDA approval in 2013. Institute physicians also are helping patients with atrial fibrillation in ways supported by the latest study findings. Compared to long-term warfarin therapy alone, use of the Watchman Left Atrial Appendage Closure device (Boston Scientific) was associated with a 40% reduction in a composite endpoint of cardiac-related death, stroke and systemic embolism in 4-year PROTECTion in Patients with Atrial Fibrillation (PROTECT AF) Trial results. Findings were presented at both the Society of Cardiovascular Angiography and Interventions and Heart Rhythm Society 2013 annual meetings. Although potentially good news for most atrial fibrillation patients, a select group cannot tolerate the antithrombic regimen required after placement of the Watchman device. Innovation to the Rescue For these patients, Institute investigators are taking the lead and closing the left atrial appendage using some innovative technology. The technique involves two wires with magnetic tips. They place one wire in an endovascular approach inside the heart, another outside, and join them together to advance the Lariat Suture Delivery Device (SentreHeart, Inc.). They then can snare, ligate and close the left atrial appendage in these high-risk patients. The Lariat is FDA approved for soft tissue removal but this off-label technique offers promise to patients with otherwise few therapeutic options. For additional information, please contact Ramon Quesada, M.D. at 786-596-5992. n Critical Advances for Critical Limb Ischemia A n integrated team of medical experts, the latest technological advances and a critical sense of timing together provide the greatest promise to patients with critical limb ischemia. One simple goal drives the multidisciplinary collaboration at Baptist Cardiac & Vascular Institute: to intervene early, aggressively and in the most minimally invasive way to avoid an otherwise inevitable limb amputation from critical limb ischemia. The interventional radiologists, vascular surgeons and other experts at the Institute work as a cohesive team. They evaluate, treat and monitor each patient and devise an individualized plan to deliver maximum benefit from the most appropriate treatment. The Institute aims to increase awareness about critical limb ischemia and the need for speedy diagnosis and timely referral among community healthcare providers. One message is to always consider critical limb ischemia in the differential diagnosis of leg pain. From simple noninvasive screening to sophisticated imaging that guides a wide range of advanced interventional technologies, patients with compromised circulation benefit when they come to the Institute. The earlier the intervention, the better the outcome for most patients. For example, leg ulcers caused by critical limb ischemia can become more and more difficult to treat. Patients may even pass a “point of no return” where the severity of tissue damage precludes complete healing, even following restoration of blood flow. From initial integrated team assessment to discharge planning, organizing all these state-of-the-art intervention options for patients with critical limb ischemia in one program has led to better patient outcomes. For additional information, please contact Barry T. Katzen, M.D., James F. Benenati, M.D., Abilio A. Coello, M.D., Ripal T. Gandhi, M.D., Howard E. Katzman, M.D., Constantino S. Peña, M.D., Alex Powell, M.D., Ignacio Rua, M.D., Shaun Samuels, M.D., Athanassios Tsoukas, M.D. or Libby Watch, M.D. at 786-596-5992. n Initial angiogram demonstrates occluded anterior and posterior tibial arteries in a patient with critical limb ischemia manifested as a nonhealing ulcer of the foot. Before After Following recanalization and angioplasty, postintervention angiogram demonstrates patent anterior tibial, posterior tibial and peroneal arteries to the foot. Dr. Barry T. Katzen Receives Society of Interventional Radiology 2013 Leaders in Innovation Award Barry T. Katzen, M.D., the Institute’s founder and medical director, received the 2013 Leaders in Innovation Award from the Society of Interventional Radiology. The Society bestows this award to clinical innovators Dr. Katzen such as Dr. Katzen who have significantly improved the quality of patient care or economics of interventional practice. The award recognizes those who develop and implement new devices, techniques or physician practice models that truly advance the field of interventional radiology. Dr. Abilio A. Coello Appointed to Society Leadership Role Baptist Cardiac & Vascular Institute vascular surgeon Abilio A. Coello, M.D., is now serving as 2013-2014 president of the Florida Vascular Society. Dr. Coello is an integral part of the multidisciplinary team Dr. Coello at the Institute with special expertise in surgical repair of lower extremity venous ulcers and endovascular repair of abdominal aortic aneurysms. Dr. Coello also is a past president of the South Florida Chapter of the American College of Surgeons and was also governor for the American College of Surgeons representing Florida. n Targeting Acute Ischemic Stroke Clot Removal Management of acute ischemic stroke can be challenging. With only one FDAapproved medical therapy — IV tissue plasminogen activator or tPA — and up to 90% severe disability or mortality possible with large cerebral vessel occlusion, the search continues for the ideal strategy to help these patients. Institute physicians are leading this quest in South Florida. They are set to launch three new clinical trials that compare the latest clot-grabbing and stent retrieval devices in conjunction with IV tPA versus tPA alone to find the optimal acute ischemic stroke intervention. For example, the Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke (Separator 3D Trial) will test if this nextgeneration clot engagement device in combination with the Penumbra aspiration thrombectomy system (both made by Penumbra, Inc.) yields better outcomes for patients with large vessel occlusion versus Penumbra clot aspiration alone. Also coming soon is the THERAPY Trial. Acute ischemic stroke patients with large clot burdens will be randomized in this study to intervention with the Separator 3D clot engagement device — a component of the Penumbra system Penumbra Separator 3D device and aspiration thrombectomy versus IV tPA alone. Patient enrollment in these innovative studies at the Institute is underway. No matter which intervention is appropriate, data suggest better outcomes when patients seek care at a high-volume stroke center with highly trained clinicians available 24/7. For additional information, please contact Italo Linfante, M.D. or Guiherme Dabus, M.D. at 786-596-5992. n Baptist Health South Florida 8900 North Kendall Drive Miami, FL 33176-2197 Change service requested NON-PROFIT ORGANIZATION U.S. Postage PAID Permit No. 2655 Miami, FL Expanding Walls and Possibilities A n ambitious $90 million expansion to Baptist Cardiac & Vascular Institute and Baptist Hospital’s Surgery Center will go beyond a brick-and-mortar expansion and renovation. After completion of construction and the opening of the new facility, patients across South Florida, the region and the world will benefit from seamless care and the latest technological innovations. The expansion also builds on the Institute’s mission to foster the best multidisciplinary team approach to patient care. This close collaboration is not only expected to optimize individual patient outcomes, but also to change in a fundamental way how different physicians work together in a setting without the traditional specialty barriers. A National Center for Aneurysm Therapy, a Center for Structural Heart Therapy and a Center for Advanced Endovascular Therapies are among the planned highlights, each designed to provide the best minimally invasive procedures for maximum patient benefit. An integrated team at the Center for Advanced Endovascular Therapy will employ advanced imaging to create unique, cutting-edge clinical interventions. The expansion will feature four new endovascular procedure suites that offer this latest technology, in addition to an expansive renovation. For patients, this means many different levels of intervention become possible in the same suite — from the least invasive therapy to complex surgery to a combination of clinical strategies, as warranted. The new expansion construction and renovation is scheduled for completion in 2016. n Construction to expand Baptist Cardiac & Vascular Institute and Baptist Hospital’s Surgery Center broke ground in 2013 and will be completed in 2016. Baptist Cardiac & Vascular Institute Leadership Physicians Founder and Medical Director Barry T. Katzen, M.D., James F. Benenati, M.D., Lawrence Blacher, M.D., Abilio A. Coello, M.D., Nestor Demorizi, M.D., Rajesh Dhairyawan, M.D., Jonathan Fialkow, M.D., Julius Gasso, M.D., Alvaro A. Gomez, M.D., Efrain H. Gonzalez, M.D., Curtis A. Hamburg, M.D., Dean Heller, M.D., Howard E. Katzman, M.D., Karl H. Lembcke, M.D., Ramon L. Lloret, M.D., Madeleen Mas, M.D., Alvaro Mayorga-Cortes, M.D., Niberto L. Moreno, M.D., Constantino Peña, M.D., Edward Peron, M.D., Gerardo A. Polanco, M.D., Alex Powell, M.D., Orlando Puente, M.D., Ramon Quesada, M.D., Jonathan S. Roberts, M.D., Ignacio Rua, M.D., Shaun Samuels, M.D., Paul Seigel, M.D., Marcus St. John, M.D., Richard E. Tannenbaum, M.D., Athanassios Tsoukas, M.D., Billy K. Yeh, M.D. Editors: Barry T. Katzen, M.D. and Ramon Lloret, M.D. Managing Editor: Amy Erez Writer: Damian McNamara Editorial Contributors: Ripal Gandhi, M.D., Jonathan S. Roberts, M.D., Adrienne Sylver Designer: Wendy Kornfield